Genome-wide examination of genetic variants associated with response to platinum-based chemotherapy in patients with small-cell lung cancer

Pharmacogenetics and Genomics

Volumn 20, Issue 6, 2010, Pages 389-395

  Wu, Chen ^a   Xu, Binghe ^b   Yuan, Peng ^b   Ott, Jurg ^c   Guan, Yin ^b   Liu, Yu ^a   Liu, Zhe ^c   Shen, Yuanyuan ^c   Yu, Dianke ^a   Lin, Dongxin ^a  

^a CANCER HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c Chinese Academy of Sciences and China National Center for Bioinformation   (China)

Author keywords

Chemotherapy; Genetic variation; Genome wide association; Lung cancer; Platinum

Indexed keywords

BREAKPOINT CLUSTER REGION PROTEIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; ONCOPROTEIN; PLATINUM COMPLEX; PROTEIN BTBD3; PROTEIN STXBP5; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOSENSITIVITY; CHROMOSOME 20P; CHROMOSOME 22P; CHROMOSOME 6Q; FEMALE; GENE FREQUENCY; GENE LOCATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTRON; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

CARBOPLATIN; CISPLATIN; ETOPOSIDE; FEMALE; GENES; GENOME; HUMANS; INUITS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; PLATINUM; POLYMORPHISM, SINGLE NUCLEOTIDE; R-SNARE PROTEINS; SMALL CELL LUNG CARCINOMA;

EID: 77952382817     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32833a6890     Document Type: Article

References (36)

1. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24:4539-4544.
2. Devesa SS, Shaw GL, Blot WJ. Changing patterns of lung cancer incidence by histological type. Cancer Epidemiol Biomarkers Prev 1991; 1:29-34.
3. Simon GR, Wagner H. Small cell lung cancer. Chest 2003; 123:259S-271S.
4. Simon GR, Ginsberg RJ, Ruckdeschel JC. Small-cell lung cancer. Chest Surg Clin N Am 2001; 11:165-188.
5. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005; 366:1385-1396.
6. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004; 350:379-392.
7. Donnelly JG. Pharmacogenetics in cancer chemotherapy: balancing toxicity and response. Ther Drug Monit 2004; 26:231-235.
8. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22:7265-7279.
9. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359:1367-1380.
10. Muller PJ, Dally H, Klappenecker CN, Edler L, Jager B, Gerst M, et al. Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients. Int J Cancer 2009; 124:1669-1674.
11. Ozols RF. Chemotherapy for advanced epithelial ovarian cancer. Hematol Oncol Clin North Am 1992; 6:879-894.
12. Chen J, Jiang R, Garces YI, Jatoi A, Stoddard SM, Sun Z, et al. Prognostic factors for limited-stage small cell lung cancer: a study of 284 patients. Lung Cancer 2008; 67:221-226.
13. Deeken JF, Figg WD, Bates SE, Sparreboom A. Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. Anticancer Drugs 2007; 18:111-126.
14. Wang Z, Xu B, Lin D, Tan W, Leaw S, Hong X, et al. XRCC1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in Chinese population. Lung Cancer 2008; 62:99-104.
15. Yu D, Zhang X, Liu J, Yuan P, Tan W, Guo Y, et al. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis. Clin Cancer Res 2008; 14:2878-2886.
16. Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin 2009; 59:42-55.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216. (Pubitemid 30099779)
18. Hoh J, Wille A, Ott J. Trimming, weighting, and grouping SNPs in human case-control association studies. Genome Res 2001; 11:2115-2199.
19. Kankova K, Stejskalova A, Pacal L, Tschoplova S, Hertlova M, Krusova D, et al. Genetic risk factors for diabetic nephropathy on chromosomes 6p and 7q identified by the set-association approach. Diabetologia 2007; 50:990-999.
20. De Quervain DJ, Poirier R, Wollmer MA, Grimaldi LM, Tsolaki M, Streffer JR, et al. Glucocorticoid-related genetic susceptibility for Alzheimer's disease. Hum Mol Genet 2004; 13:47-52.
21. Papassotiropoulos A, Wollmer MA, Tsolaki M, Brunner F, Molyva D, Lutjohann D, et al. A cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease. J Clin Psychiatry 2005; 66:940-947.
22. Cavalleri GL, Weale ME, Shianna KV, Singh R, Lynch JM, Grinton B, et al. Multicentre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types: a case-control study. Lancet Neurol 2007; 6:970-980.
23. Hao K, Xu X, Laird N, Wang X, Xu X. Power estimation of multiple SNP association test of case-control study and application. Genet Epidemiol 2004; 26:22-30.
24. Heidema AG, Boer JM, Nagelkerke N, Mariman ECM, van der ADL, Feskens EJ. The challenge for genetic epidemiologists: how to analyze large numbers of SNPs in relation to complex diseases. BMC Genet 2006; 7:23.
25. Heidema AG, Feskens EJ, Doevendans PA, Ruven HJ, van Houwelingen HC, Mariman EC, et al. Analysis of multiple SNPs in genetic association studies: comparison of three multi-locus methods to prioritize and select SNPs. Genet Epidemiol 2007; 31:910-921.
26. Whitlock MC. Combining probability from independent tests: the weighted Z-method is superior to Fisher's approach. J Evol Biol 2005; 18:1368-1373.
27. Yang JJ, Cheng C, Yang W, Pei D, Cao X, Fan Y, et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 2009; 301:393-403.
28. Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004; 10:4939-4943.
29. Kim HT, Lee JE, Shin ES, Yoo YK, Cho JH, Yun MH, et al. Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy. J Clin Oncol 2008; 26:5972-5979.
30. Wu X, Lu C, Ye Y, Chang J, Yang H, Lin J, et al. Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics 2008; 18:955-965.
31. Damgaard T, Knudsen LM, Dahl IM, Gimsing P, Lodahl M, Rasmussen T. Regulation of the CD56 promoter and its association with proliferation, anti-apoptosis and clinical factors in multiple myeloma. Leuk Lymphoma 2009; 50:236-246.
32. Onganer PU, Seckl MJ, Djamgoz MB. Neuronal characteristics of small-cell lung cancer. Br J Cancer 2005; 93:1197-1201.
33. Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009; 113:1619-1630.
34. Chanock SJ, Manolio T, Boehnke M, Boerwinkle E, Hunter DJ, Thomas G, et al. Replicating genotype-phenotype associations. Nature 2007; 447:655-660.
35. Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer 2001; 1:99-108.
36. Wellcome Trust Case Control Consortium. Genome-wide association study of 14 000 cases of seven common diseases and 3000 shared controls. Nature 2007; 447:661-678.